Please sign in to follow a disease.
New hope for myeloma patients who have run out of options
NCT ID NCT05757973
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides talquetamab, a single-drug treatment, to people with multiple myeloma that has returned or is hard to treat. Participants must have tried all other available therapies and cannot join a clinical trial. The goal is to offer a potential treatment option when no others remain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant diagnosed with relapsed or refractory multiple, myeloma * Participant exhausted all commercially approved and clinically appropriate treatment options, and is ineligible for a clinical trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Relapsed or refractory multiple myeloma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
- Can a new drug combo outsmart Hard-to-Treat myeloma?
- Engineered immune cells take on Hard-to-Treat myeloma
- Home infusion for myeloma drug passes early safety check
- New hope for multiple myeloma: phase 3 trial launches
- New CAR T-Cell therapy targets Hard-to-Treat myeloma